Skip to content
LISTE DE DIFFUSION
Linkedin page opens in new window
AB Science
Discipline serving the patients
AB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • FR
  • EN
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Audio replay of the June 30 2021 Combined Shareholders’ Meeting

You are here:
  1. Home
  2. Uncategorised
  3. Audio replay of the June…

Replay of the audio transcript in the audio player below:

https://www.ab-science.com/wp-content/uploads/2021/07/2021-07-01_AG_AB_Science_du_30_Juin_2021.mp3
Categories: Uncategorised, UncategorizedBy admin1 July 2021
Partager cet article
Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Share on WhatsAppShare on WhatsApp

Author: admin

https://ab-science.excalibra.com

Post navigation

PreviousPrevious post:Results of the Combined General Shareholders’ Meeting of June 30, 2021NextNext post:Validation of the Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France
AB Science AB Science

La rigueur au service des patients. Discipline serving the patients

Accéder aux quatre espaces Access the four spaces

AB SCIENCE
HEADQUARTERS

3, Avenue George V – 75008 PARIS – FRANCE
Tel.: +33 (0)1 47 20 00 14
Fax: +33 (0)1 47 20 24 11

GENERAL INQUIRIES

contact@ab-science.com

PRODUCT INQUIRIES

masivet@ab-science.com

JOB INQUIRIES

careers@ab-science.com

CLINICAL INQUIRIES

clinical@ab-science.com

MEDIA / FINANCIAL INQUIRIES

investors@ab-science.com

PHARMACOVIGILANCE

pharmacovigilance@ab-science.com
Fax : +33 (0)1 47 20 10 82

© 2026 AB SCIENCE
Go to Top